Project Grant R44AG091903
Award Date
4/1/25
Completion Date
3/31/26
Dollars Obligated
$500K
Federal Agency
National Institute on Aging
Awardee
Nuravax, Inc. (RZ48G7JQMQF5)
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $356,174 to The Regents of the University of California, San Francisco (UCSF) to conduct in vivo testing of structure-based vaccine candidates targeting Alzheimer's disease. The goal is to determine the efficacy of an active immunization strategy in preserving cognitive and neural function by slowing the formation of amyloid-beta or tau protein aggregation in the brain. The project will...
This $574,474 federal Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) supports the development and preclinical testing of self-adjuvanting peptide nanofiber (PNF) vaccines targeting amyloid-beta (Aβ) and tau proteins for the treatment of Alzheimer's disease (AD) and frontotemporal dementia (FTD). The Washington University in St. Louis, the prime awardee, will lead this effort in collaboration with the University of Texas Medical Branch at Galveston as a...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) provides $431,750 to develop and validate a novel immuno-gene therapy targeting pathogenic tau conformations associated with Alzheimer's disease and related tauopathies. The project aims to use recombinant adeno-associated viruses (AAVs) to deliver a single-chain fragment variable (scFv) antibody called TNT2 that specifically binds to the phosphatase-activating domain (PAD) of pathogenic tau...
This Project Grant award from the National Institute on Aging (NIA), under the Aging Research Federal Grant Program (CFDA 93.866), provides $499,911 to Aeton Therapeutics Inc. to develop an anti-tau monoclonal antibody treatment for Alzheimer's disease. The key objectives are to: 1) evaluate the effectiveness of Aeton's lead candidate AT-01 in treating neural cells and organoids, compared to another anti-tau antibody, and 2) determine the efficacy and safety of AT-01 versus the comparator in...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $431,750 to a partnership between Henry Ford Health and Michigan State University Health Sciences. The funding will support the development and evaluation of a novel immuno-gene therapy targeting oligomeric tau, a key driver of neurodegeneration in tauopathies like Alzheimer's disease. Specifically, the project aims to engineer a single-chain antibody fragment (scFv) derived from the anti-tau...
This Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) provides $504,732 to Aphios Corp to develop a novel Alzheimer's disease therapeutic. The goal is to create targeted nanoparticles loaded with an anti-CCR5 drug that can address brain inflammation associated with Alzheimer's. In Phase I, the project will (1) nanoencapsulate the anti-CCR5 drug into targeted and non-targeted nanoparticles, characterize their properties, and (2) evaluate the impact on in...
This Cooperative Agreement award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides funding of $1,791,614 to support the development and initial clinical evaluation of a vaccine targeting the pathological alpha-synuclein protein for the treatment of Lewy body dementia (LBD).
The key products and services to be delivered under this award include: (1) manufacturing of an engineering-run recombinant protein vaccine candidate (PV-1950R) for safety and toxicology studies;...
This Project Grant award, valued at $109,595.00, was provided by the National Institute on Aging (NIA) under the Aging Research federal grant program (CFDA 93.866). The award supports comprehensive microscopic studies to characterize a novel nonhuman primate model of Alzheimer's disease pathology at the University of California, Davis.
The research aims to:
Determine the regional and laminar patterns of tau-based neuropathology and neuronal loss within the entorhinal cortex, hippocampus, and...
The National Institute on Aging (NIA), through its Aging Research Federal Grant Program (CFDA 93.866), awarded a $408,638 Project Grant to Virginia Commonwealth University (VCU) with a performance period from August 1, 2024 to July 31, 2026. The grant will fund research to investigate the effect of trans-synaptic spread of pathogenic tau protein from the entorhinal cortex to the hippocampus, a key brain region affected in Alzheimer's disease. The research will use adeno-associated viral...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $2,342,415 to the University of California, Irvine (UC Irvine) to investigate the adverse cerebrovascular responses to antibodies targeting beta-amyloid, a key component associated with Alzheimer's disease. The research aims to:
Elucidate the temporal sequence and vascular aging factors that contribute to adverse central nervous system blood vessel responses to passive...